PRESS RELEASE published on 06/26/2024 at 07:30, 1 year 7 months ago Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study Crossject provides insights on ZEPIZURE® potential in light of RAMPART and its bioequivalence study. IM midazolam favored over IV lorazepam for emergency epilepsy management Crossject ZEPIZURE RAMPART Study Bioequivalence Study Emergency Epilepsy Management
BRIEF published on 06/18/2024 at 12:35, 1 year 7 months ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Droits De Vote Capital Social AMF Pharmacie Spécialisée Crossject
BRIEF published on 06/18/2024 at 12:35, 1 year 7 months ago Crossject: Information relating to the total number of voting rights and shares making up the share capital Share Capital Voting Rights AMF Crossject Specialized Pharmacy
PRESS RELEASE published on 06/18/2024 at 12:30, 1 year 7 months ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Publication du nombre total de droits de vote et d'actions de CROSSJECT au 31 mai 2024 conformément aux réglementations. Détails sur le capital social Droits De Vote Capital Social AMF Crossject Pharma
BRIEF published on 06/13/2024 at 09:41, 1 year 7 months ago Crossject : Information sur le nombre de droits de vote et d'actions Droits De Vote Capital Social Actions 2024 Crossject
BRIEF published on 06/13/2024 at 09:41, 1 year 7 months ago Crossject: Information on the number of voting rights and shares Share Capital Voting Rights Actions 2024 Crossject
PRESS RELEASE published on 06/13/2024 at 09:36, 1 year 7 months ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Crossject publie le nombre total de droits de vote et d'actions au 31 mai 2024 conformément aux normes réglementaires Droits De Vote Capital Social Actions Crossject Pharma
BRIEF published on 06/12/2024 at 07:35, 1 year 7 months ago Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord Crossject ZEPIZURE® Dan Chiche Directeur Médical
BRIEF published on 06/12/2024 at 07:35, 1 year 7 months ago Crossject Appoints Dan Chiche, MD as North America Chief Medical Officer Crossject ZEPIZURE® Dan Chiche Medical Director
PRESS RELEASE published on 06/12/2024 at 07:30, 1 year 7 months ago Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord Nomination de Dan Chiche, MD en tant que Directeur Médical Amérique du Nord chez Crossject, renforçant l'équipe dirigeante et la présence aux États-Unis pour lancer ZEPIZURE en 2025 Amérique Du Nord Crossject ZEPIZURE Dan Chiche Directeur Médical
Published on 01/30/2026 at 08:35, 53 minutes ago Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 1 hour 28 minutes ago Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 7 hours 13 minutes ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 9 hours 28 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 10 hours 28 minutes ago PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/30/2026 at 09:00, 27 minutes ago Original-Research: 123fahrschule SE (von NuWays AG): BUY
Published on 01/30/2026 at 08:00, 1 hour 27 minutes ago Ørsted to present its annual report for 2025 on February 6
Published on 01/30/2026 at 08:30, 58 minutes ago Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés
Published on 01/30/2026 at 08:00, 1 hour 28 minutes ago AMA : Chiffre d'affaires du 4ème trimestre et de l'année 2025
Published on 01/29/2026 at 18:30, 14 hours 58 minutes ago ALPOU - Groupe POULAILLON chiffre d'affaires trimestriel T1 2025-2026 et Focus sur les activités
